Brief: Vertex To Acquire Crinetics Pharmaceuticals In $10 Billion Deal
06/07/2026 21:16
BRIEF-Vertex To Acquire Crinetics Pharmaceuticals In $10 Billion Deal July 6 (Reuters) -
VERTEX TO ACQUIRE CRINETICS PHARMACEUTICALS
VERTEX TO BUY CRINETICS FOR $85 PER SHARE IN $10 BILLION DEAL
VERTEX WILL ACQUIRE CRINETICS FOR $85.00 PER SHARE IN CASH
VERTEX TO FINANCE DEAL USING CASH ON HAND & DEBT
DEAL EXPECTED TO BE ACCRETIVE VERTEX'S TO NON-GAAP OPERATING INCOME IN 2029
FINANCING SUPPORTED BY $4.5 BILLION OF FULLY COMMITTED BRIDGE FINANCING FROM BANK OF AMERICA, MORGAN STANLEY SENIOR FUNDING
Source text: ID:nBw1b3TBba
Further company coverage: CRNX.OVRTX.O
((Reutersbriefs@thomsonreuters.com;))
Recent news on Vertex Pharmaceuticals Incorporated
See all newsBrief: Vertex Appoints Daniel Brennan To Its Board Of Directors
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
Vertex rises after kidney disease drug shows promise in mid-stage study
Brief: Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR By -42.7% At Week 13 In AMKD With Modest Proteinuria